The acquisition will expand PharmaLogic’s US radiopharmaceutical manufacturing capacity and establish a transatlantic platform for radioligand therapies.
PharmaLogic Holdings Corp. has agreed to acquire the contract development and manufacturing organisation (CDMO) business and Springfield manufacturing facility in New Jersey, US, from Lantheus Holdings, Inc. The financial terms of the transaction have not been disclosed.
The Springfield facility specialises in radiopharmaceutical manufacturing and has experience in theranostic manufacturing, research and clinical development. Following completion of the acquisition, its team will join Agilera, PharmaLogic’s therapeutic CDMO business.
The agreement also includes a long-term supply arrangement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
The acquisition will expand PharmaLogic’s US capacity for radiopharmaceutical therapeutics and establish what the company describes as the first transatlantic platform offered by a therapeutic CDMO, supporting radioligand therapies (RLTs) from early clinical development through to commercial launch and global supply.
Agilera has more than 15 years of experience supporting the development and commercial launch of RLTs and currently supplies an alpha therapy to more than 30 countries.
Etienne Montagut, President and Chief Executive Officer of PharmaLogic, said: “This acquisition strengthens Agilera’s unique capabilities in radioligand therapies and expands our capacity in the U.S.”
The transaction remains subject to applicable regulatory review and customary closing conditions. Both companies will continue to operate independently until completion.
No comments yet